Ildong started developing a treatment for COVID-19

By Nho, Byung Chul | translator Choi HeeYoung

21.11.26 06:00:38

가나다라 0

Co-clinical with Shionogi Pharmaceutical, contributes to establishing treatment sovereignty through localization

Clinical trials are conducted on 200 asymptomatic, mild, and severe patients in Korea

Attention is focusing on whether or not the 3rd oral treatment in the world will be released after Pfizer and MSD

Ildong Pharmaceutical and Shionogi Pharmaceutical have begun joint development of oral COVID-19 treatments, drawing keen attention to whether they will succeed in commercializing them in the future.

Ildong Pharmaceutical officially announced on the 17th that it will participate in the development of S-217622 as a candidate for oral COVID-19 treatment along with Shionogi Pharmaceutical, and attention is being paid to whether it will create the third drug in the world to contribute to the end of the pandemic after Pfizer and MSD.

Accordingly, Ildong Pharmaceutical plans to start the development process as soon as the recruitment of patients is completed after obtaining IND approval for the

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)